The Supreme Court has dismissed a public-interest litigation (PIL) filed against Ranbaxy for allegedly manufacturing and selling substandard drugs in India. The petitioner failed to bring in evidence against Ranbaxy.
Earlier in June, PIL appeal was filed in the Supreme Court against the company’s directors for allegedly manufacturing and selling adulterated drugs. Manohar Lal Sharma, the petitioner, also sought sealing of the company’s manufacturing facilities at Paonta Sahib and Devas in Madhya Pradesh, besides mentioning the Central Bureau of Investigation (CBI) as one of the respondents in the case. The PIL came in the wake of the Indian pharma major being fined $500 million by the U.S. Food and Drug Administration (USFDA) for making and selling 'adulterated' drugs
Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
